| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 132 |
| 1 | PEMBROLIZUMAB | 116 |
| 2 | BEVACIZUMAB | 112 |
| 3 | LETROZOLE | 93 |
| 4 | FUROSEMIDE | 90 |
| 5 | FULVESTRANT | 88 |
| 6 | PACLITAXEL | 88 |
| 7 | CYCLOPHOSPHAMIDE | 77 |
| 8 | CYCLOPHOSPHAMIDE FOR INJECTION | 77 |
| 9 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 77 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TAZEMETOSTAT | 14 | 0.0086 |
| 1 | GEFITINIB | 30 | 0.0033 |
| 2 | ERLOTINIB HYDROCHLORIDE | 40 | 0.0032 |
| 3 | FULVESTRANT | 88 | 0.0026 |
| 4 | AFATINIB | 16 | 0.0024 |
| 5 | EXEMESTANE | 51 | 0.0024 |
| 6 | PEMETREXED DISODIUM | 72 | 0.0018 |
| 7 | OSIMERTINIB | 60 | 0.0018 |
| 8 | BENDAMUSTINE HYDROCHLORIDE | 14 | 0.0016 |
| 9 | ERGOCALCIFEROL | 47 | 0.0016 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 381 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 199 |
| 2 | Platinum-based Drug [EPC] | 196 |
| 3 | Corticosteroid [EPC] | 185 |
| 4 | Aromatase Inhibitor [EPC] | 153 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 131 |
| 6 | Microtubule Inhibitor [EPC] | 127 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 121 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 112 |
| 9 | Alkylating Drug [EPC] | 98 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Estrogen Receptor Antagonist [EPC] | 88 | 0.0022 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 199 | 0.0020 |
| 2 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 3 | 0.0020 |
| 3 | Provitamin D2 Compound [EPC] | 47 | 0.0016 |
| 4 | Aromatase Inhibitor [EPC] | 153 | 0.0013 |
| 5 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 7 | 0.0011 |
| 6 | Histone Deacetylase Inhibitor [EPC] | 4 | 0.0010 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 9 | 0.0010 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 21 | 0.0010 |
| 9 | Guanylate Cyclase-C Agonist [EPC] | 2 | 0.0010 |